Skip to main content
Cancer DiagnosticsNational Health Service· 6 min read· in Health

NICE Backs Seven-Minute Capsule Sponge Test for Early Oesophageal Cancer Detection in Primary Care

The English health service is set to roll out a less invasive 'sponge on a string' diagnostic tool to GP clinics, targeting patients with persistent acid reflux. The seven-minute test aims to catch oesophageal cancer earlier while reducing the burden on hospital endoscopy units.

By Sofia Delgado

Share this story

Listen

The National Institute for Health and Care Excellence has issued draft guidance recommending a rapid "sponge on a string" test for widespread use across the English health service. The diagnostic tool is designed to identify cellular changes that precede oesophageal cancer in patients suffering from persistent acid reflux.[1][2]

Rather than requiring a hospital visit for an invasive endoscopy, patients will be able to undergo the procedure at their local general practice or community diagnostic centre. The shift moves cancer screening directly into primary care settings, eliminating the need for sedation and specialist surgical teams.[1][3]

The recommendation covers two specific capsule sponge technologies, Cytosponge and EndoSign, which have already been evaluated in regional pilot schemes. If the guidance is finalised, the National Health Service will fund the tests and make them consistently available to eligible patients nationwide.[1][2]

"Oesophageal cancer is very difficult to treat when it is diagnosed at a later stage, so identifying people sooner is really important," said Professor Jonathan Benger, chief executive of NICE. He noted that the technology offers a quicker way to detect concerning changes associated with the disease.[1][3]

A seven-minute procedure

The entire testing process takes approximately seven minutes from start to finish. A patient swallows a small capsule attached to a surgical thread, which travels down the food pipe and into the stomach just like a standard pill.[2][4]

Once inside the stomach, the capsule's outer casing dissolves over the course of a few minutes. This releases a small, medical-grade sponge that naturally expands to its full size within the gastric cavity.[1][5]

The capsule dissolves in the stomach, releasing a sponge that collects cells as it is retrieved.

A trained healthcare professional then gently pulls the thread to retrieve the expanded sponge back up through the throat. As the textured surface passes through the oesophagus, it collects a comprehensive sample of cells from the lining of the food pipe.[2][3]

Those collected cells are subsequently sent to a laboratory for analysis, where pathologists look for the specific abnormalities that indicate Barrett's oesophagus or early-stage cancer. Patients whose results show concerning cellular changes are then referred for a traditional diagnostic endoscopy to confirm the findings.[1][3]

Clinical data reviewed by the NICE committee showed that around 95 percent of patients successfully swallow the capsule, often on their first attempt. The procedure requires only a single trained healthcare worker to administer, drastically reducing the personnel needed for screening.[1][3]

Targeting long-term acid reflux

The primary target for the rollout is patients experiencing persistent gastro-oesophageal reflux disease, commonly known as acid reflux. Over time, stomach acid washing back up into the food pipe can cause the cells lining the lower oesophagus to change and mutate.[1][2]

This cellular mutation is known as Barrett's oesophagus, a condition that currently affects an estimated 1 to 2 percent of the adult population. While the vast majority of people with the condition will never develop tumours, it remains a significant risk factor for oesophageal adenocarcinoma.[1][3]

More than 9,000 people are diagnosed with oesophageal cancer in the United Kingdom every year. Because the disease often presents with vague symptoms like indigestion or difficulty swallowing, it is frequently caught at an advanced stage when survival rates drop sharply.[2][4]

Clinical trials show that 95 percent of patients successfully swallow the capsule on their first or second attempt.

"Many people have acid reflux, and having an easier way to check for changes in the lining of the oesophagus can make a big difference for patients," said Professor Peter Johnson, the national clinical director for cancer at NHS England.[1][2]

Beyond initial screening, the draft guidance also approves the capsule sponge for monitoring patients who have already been diagnosed with Barrett's oesophagus. These individuals require periodic surveillance to ensure their cellular changes have not progressed into malignancy.[1][5]

Relieving hospital bottlenecks

A traditional endoscopy requires a doctor to pass a thin, flexible tube equipped with a camera down a patient's throat. The procedure demands a dedicated endoscopy suite, at least two nurses, an endoscopist, and often leaves the patient requiring recovery time from sedation.[1][3]

Demand for these hospital-based endoscopy services currently outstrips capacity across many parts of the NHS. The resulting backlog means that some high-risk patients with Barrett's oesophagus are not receiving their recommended surveillance checks on schedule.[1][6]

By moving the initial screening step into community clinics, health officials expect to significantly reduce the burden on acute hospitals. Professor Johnson noted that the shift will help the NHS free up specialist resources to find and treat cancers at an earlier stage.[1][2]

The capsule sponge tests are the first technologies to be assessed under the government's new National HealthTech Access Programme. The initiative brings together NICE, the Department of Health and Social Care, and the Medicines and Healthcare products Regulatory Agency to streamline approvals.[1][3]

Illustration: Moving diagnostic screening into community centres is expected to relieve pressure on acute hospital endoscopy units.

Streamlining national access

The programme was established to fast-track high-impact medical devices, diagnostics, and digital tools into routine clinical use across the health service. It guarantees that once a technology is approved, eligible patients across England will have consistent access regardless of their postcode.[1][3]

"Capsule sponge tests show how innovative health technologies can improve people's experience of care and help the NHS use its resources more effectively," said Thomas Slater, director of HealthTech at NICE. He framed the rollout as a model for future diagnostic adoption.[1][2]

Evidence presented to the independent committee indicated that patients strongly prefer the sponge test over a traditional endoscopy. The community-based procedure avoids the anxiety of a hospital visit, requires no fasting period, and eliminates the risks associated with intravenous sedation.[1][5]

The capsule method also bypasses the rare but serious complications linked to endoscopic cameras, such as accidental bleeding or physical damage to the oesophageal lining. While some patients report a temporary sore throat or mild irritation after the sponge is removed, severe adverse events are highly uncommon.[1][3]

Patient preference and safety

Development of the technology has been heavily backed by Cancer Research UK and the National Institute for Health and Care Research. The tests were initially validated in the BEST3 clinical trial, which demonstrated that the sponge method identified ten times more cases of Barrett's oesophagus than standard GP care.[1][3]

The diagnostic approach is currently being evaluated further through the £7.6 million BEST4 screening study. That ongoing trial includes the deployment of mobile screening units, designed to bring the testing infrastructure directly into underserved communities and high-footfall areas.[1][3]

Researchers hope the mobile units will reach populations that typically avoid clinical settings or struggle to secure GP appointments. By lowering the barrier to entry, the health service aims to catch cellular mutations years before they progress into symptomatic cancer.[1][3]

Health authorities caution that no diagnostic tool is flawless, and a negative sponge result does not guarantee the absolute absence of disease. Patients who pass the screening will still receive guidance on monitoring their symptoms and returning if their acid reflux worsens.[1][5]

Health authorities caution that no diagnostic tool is flawless, and a negative sponge result does not guarantee the absolute absence of disease.

The draft recommendations remain open for public consultation until December 7, 2026. The committee will review the feedback before issuing its final guidance, which is expected to mandate NHS funding and nationwide adoption by February 2027.[1][3]

Key points

  1. NICE has issued draft guidance recommending the Cytosponge and EndoSign capsule tests for routine use across the NHS.
  2. The seven-minute procedure can be performed in GP surgeries, eliminating the need for hospital visits and intravenous sedation.
  3. The test targets patients with persistent acid reflux to detect Barrett's oesophagus, a condition that increases the risk of oesophageal cancer.
  4. Health officials expect the community-based screening to significantly reduce the current backlog in hospital endoscopy units.

What we don’t know

  • Whether the NHS will be able to train enough primary care staff to administer the tests at the scale required by February 2027.
  • The exact cost savings the health service will realise by diverting patients away from hospital endoscopy units.
  • How quickly the mobile screening vans tested in the BEST4 trial will be deployed to underserved regions.

How we got here

  1. 2020

    The BEST3 clinical trial demonstrates that the capsule sponge identifies ten times more cases of Barrett's oesophagus than standard GP care.

  2. 2024

    The £7.6 million BEST4 screening trial launches, deploying mobile testing vans to evaluate community-based screening.

  3. Nov 16, 2026

    NICE publishes draft guidance recommending the Cytosponge and EndoSign tests for routine NHS use.

  4. Dec 7, 2026

    Public consultation on the draft recommendations concludes.

  5. Feb 2027

    Final NICE guidance is expected to mandate nationwide NHS funding and rollout.

Clinical Regulators 40%Oncology Specialists 35%Patient Advocates 25%
Clinical Regulators
Focus on standardising access to proven technologies and reducing regional variations in care.
Oncology Specialists
Prioritise early detection methods that catch cellular mutations before they develop into advanced cancer.
Patient Advocates
Value diagnostic tools that are less invasive, require no sedation, and can be accessed close to home.

Perspectives this story doesn't cover

  • General Practitioners (GPs)
  • Patients awaiting endoscopy

Sources

Source coverage

6 outlets

3 viewpoints surfaced

Clinical Regulators 40%Oncology Specialists 35%Patient Advocates 25%
  1. [1]NICEClinical Regulators

    Less invasive capsule sponge tests could help detect oesophageal cancer earlier

    Read on NICE →
  2. [2]The IndependentOncology Specialists

    'Sponge on a string' oesophageal cancer test endorsed for NHS roll-out

    Read on The Independent →
  3. [3]National Health ExecutiveClinical Regulators

    NICE backs capsule sponge test to detect oesophageal cancer earlier

    Read on National Health Executive →
  4. [4]Surrey LivePatient Advocates

    Thousands of people with indigestion to be offered cancer test

    Read on Surrey Live →
  5. [5]The Medical GazetteOncology Specialists

    Swallowable sponge test for early detection of oesophageal cancer: UK draft recommendation

    Read on The Medical Gazette →
  6. [6]Patient Safety LearningPatient Advocates

    Cancer 'sponge' tests could be offered to more people with bad indigestion

    Read on Patient Safety Learning →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.